Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 14

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Identification of a novel tedizolid resistance mutation in rpoB of MRSA after in vitro serial passage

Shen, Tianwei, Penewit, Kelsi, Waalkes, Adam, Xu, Libin, Salipante, Stephen J, Nath, Abhinav, Werth, Brian J · 2021 · Journal of Antimicrobial Chemotherapy

Abstract

Objectives: Tedizolid is an oxazolidinone antimicrobial with activity against Gram-positive bacteria, including MRSA. Tedizolid resistance is uncommon and tedizolid’s capacity to select for cross-resistance to other antimicrobials is incompletely understood. The objective of this study was to further explore the phenotypic and genetic basis of tedizolid resistance in MRSA. Methods: We selected for tedizolid resistance in an MRSA laboratory strain, N315, by serial passage until an isolate with an MIC ≥1 log2 dilution above the breakpoint for resistance (≥2 mg/L) was recovered. This isolate was subjected to WGS and susceptibility to a panel of related and unrelated antimicrobials was tested in order to determine cross-resistance. Homology modelling was performed to evaluate the potential impact of the mutation on target protein function. Results: After 10 days of serial passage we recovered a phenotypically stable mutant with a tedizolid MIC of 4 mg/L. WGS revealed only one single nucleotide variant (A1345G) in rpoB, corresponding to amino acid substitution D449N. MICs of linezolid, chloramphenicol, retapamulin and quinupristin/dalfopristin increased by ≥2 log2 dilutions, suggesting the emergence of the so-called ‘PhLOPSa’ resistance phenotype. Susceptibility to other drugs, including rifampicin, was largely unchanged. Homology models revealed that the mutated residue of RNA polymerase would be unlikely to directly affect oxazolidinone action. Conclusions: To the best of our knowledge, this is the first time that an rpoB mutation has been implicated in resistance to PhLOPSa antimicrobials. The mechanism of resistance remains unclear, but is likely indirect, involving σ-factor binding or other alterations in transcriptional regulation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jac/dkaa422

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 25

  1. Kisgen, 2014, Tedizolid: a new oxazolidinone antimicrobial, Am J Health Syst Pharm, 71, 621, 10.2146/ajhp130482 · DOI
  2. Shaw, 2008, In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains, Antimicrob Agents Chemother, 52, 4442, 10.1128/AAC.00859-08 · DOI · Paper page
  3. Freitas, 2018, Dissemination of Staphylococcus epidermidis ST22 with stable, high-level resistance to linezolid and tedizolid in the Greek-Turkish region (2008-2016, Infect Control Hosp Epidemiol, 39, 492, 10.1017/ice.2018.5 · doi:10.1017/ice.2018.5
  4. Zhanel, 2015, Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens, Drugs, 75, 253, 10.1007/s40265-015-0352-7 · DOI · Paper page
  5. Wang, 2015, A novel gene, optrA, that confers transferable resistance to oxazolidinones and phenicols and its presence in Enterococcus faecalis and Enterococcus faecium of human and animal origin, J Antimicrob Chemother, 70, 2182, 10.1093/jac/dkv116 · DOI · Paper page
  6. Liu, 2018, Prevalence, resistance pattern, and molecular characterization of Staphylococcus aureus isolates from healthy animals and sick populations in Henan Province, China, Gut Pathog, 10, 31, 10.1186/s13099-018-0254-9 · doi:10.1186/s13099-018-0254-9
  7. Fan, 2016, Presence of the optrA gene in methicillin-resistant Staphylococcus sciuri of porcine origin, Antimicrob Agents Chemother, 60, 7200, 10.1128/AAC.01591-16 · DOI
  8. Locke, 2009, Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700), Antimicrob Agents Chemother, 53, 5265, 10.1128/AAC.00871-09 · DOI · Paper page
  9. Silverman, 2001, Resistance studies with daptomycin, Antimicrob Agents Chemother, 45, 1799, 10.1128/AAC.45.6.1799-1802.2001 · DOI · Paper page
  10. Roach, 2015, A year of infection in the intensive care unit: prospective whole genome sequencing of bacterial clinical isolates reveals cryptic transmissions and novel microbiota, PLoS Genet, 11, e1005413, 10.1371/journal.pgen.1005413 · DOI · Paper page
  11. Yang, 2015, Protein structure and function prediction using I-TASSER, Curr Protoc Bioinformatics, 52, 5.8.1, 10.1002/0471250953.bi0508s52 · DOI · Paper page
  12. Kryshtafovych, 2018, Evaluation of the template-based modeling in CASP12, Proteins, 86 Suppl 1, 321, 10.1002/prot.25425 · DOI
  13. Berbers, 2020, Combining short and long read sequencing to characterize antimicrobial resistance genes on plasmids applied to an unauthorized genetically modified Bacillus, Sci Rep, 10, 4310, 10.1038/s41598-020-61158-0 · DOI
  14. Alifano, 2015, Rifampicin-resistance, rpoB polymorphism and RNA polymerase genetic engineering, J Biotechnol, 202, 60, 10.1016/j.jbiotec.2014.11.024 · DOI
  15. Zhou, 2012, Molecular characterization of rifampicin-resistant Staphylococcus aureus isolates in a Chinese teaching hospital from Anhui, China, BMC Microbiol, 12, 240, 10.1186/1471-2180-12-240 · DOI
  16. Demo, 2017, Structure of RNA polymerase bound to ribosomal 30S subunit, eLife, 6, e28560, 10.7554/eLife.28560 · DOI
  17. Kohler, 2017, Architecture of a transcribing-translating expressome, Science, 356, 194, 10.1126/science.aal3059 · DOI · Paper page
  18. Cui, 2010, An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus, Antimicrob Agents Chemother, 54, 5222, 10.1128/AAC.00437-10 · DOI · Paper page
  19. Bæk, 2015, Stepwise decrease in daptomycin susceptibility in clinical Staphylococcus aureus isolates associated with an initial mutation in rpoB and a compensatory inactivation of the clpX gene, Antimicrob Agents Chemother, 59, 6983, 10.1128/AAC.01303-15 · DOI
  20. Harms, 2004, Alterations at the peptidyl transferase centre of the ribosome induced by the synergistic action of the streptogramins dalfopristin and quinupristin, BMC Biol, 2, 4, 10.1186/1741-7007-2-4 · DOI · Paper page
  21. Hansen, 2003, Structures of five antibiotics bound at the peptidyl transferase center of the large ribosomal subunit, J Mol Biol, 330, 1061, 10.1016/S0022-2836(03)00668-5 · DOI · Paper page
  22. Ippolito, 2008, Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit, J Med Chem, 51, 3353, 10.1021/jm800379d · DOI · Paper page
  23. Schlünzen, 2001, Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria, Nature, 413, 814, 10.1038/35101544 · DOI · Paper page
  24. Davidovich, 2007, Induced-fit tightens pleuromutilins binding to ribosomes and remote interactions enable their selectivity, Proc Natl Acad Sci USA, 104, 4291, 10.1073/pnas.0700041104 · DOI · Paper page
  25. Bae, 2015, Structure of a bacterial RNA polymerase holoenzyme open promoter complex, eLife, 4, e08504, 10.7554/eLife.08504 · DOI · Paper page

Cited by

Metadata

Authors
Shen, T., Penewit, K., Waalkes, A., Xu, L., Salipante, S. J., Nath, A., & Werth, B. J.
Affiliations
  • Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, WA, USA
  • Department of Laboratory Medicine, School of Medicine, University of Washington, Seattle, WA, USA
  • Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, WA, USA
Venue
Journal of Antimicrobial Chemotherapy
Published
2020-10-14
Volume
76
Issue
2
Pages
292-296
ISSN
  • 0305-7453
  • 1460-2091
Cited by
14
References
2
Language
en
Funders
  • National Institute of Allergy and Infectious Diseases (1R21AI132994, 1R01AI136979)
  • National Institutes of Health
  • Cystic Fibrosis Foundation (SINGH19R0)
  • University of Washington

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.